A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON)
Clinical trial NCT05311176 · TERMINATED
Trial details
- NCT number
- NCT05311176
- Sponsor
- Imugene Limited
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-17
- Primary completion
- 2024-04-04
- Enrollment
- 7
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.